In The News Posted August 22, 2019 Share Posted August 22, 2019 LUND, Sweden, Aug. 22, 2019 /PRNewswire/ -- "We are executing according to plan. Our lead candidate BI-1206 has shown encouraging initial data in hematological cancers, and has now also entered clinical trials in solid cancer," Martin Welschof, CEO BioInvent Financial information Second... View the full article Link to comment Share on other sites More sharing options...
Recommended Posts
Archived
This topic is now archived and is closed to further replies.